Bio-Rad looks for a bottom as lab funding stays weak
- Q2 2026 sales fell 1.9% on a currency-neutral basis, driven by Life Science weakness.
- Life Science fell 5.1% currency-neutral as academic research funding stayed weak.
- Clinical Diagnostics grew slightly by 0.3% currency-neutral, fighting conflict pressure in the Middle East.
- Gross margin ticked up to 53.1% in Q2 2026, offering a faint sign of cost stability.
- The company holds a large Sartorius AG equity stake, which can swing reported results apart from the core business.
Searching for a floor
Bio-Rad has useful products and many repeat customers. Its tools help labs run research, test blood, check quality, and support clinical testing. That gives the company a real base of demand.
The problem is a stalled recovery. Q2 2026 sales fell 1.9% on a currency-neutral basis. The Life Science segment fell 5.1% currency-neutral because academic research funding remains weak, especially in the Americas.
The larger Clinical Diagnostics segment managed a slight 0.3% currency-neutral gain in Q2 2026. This happened despite regional conflicts in the Middle East that continue to disrupt demand in the EMEA region. Management expects that conflict pressure to last through the rest of 2026.
The bull case points to faint stabilization, anchored by the slight growth in diagnostics and a small gross margin improvement to 53.1%. The bear case is simpler: organic growth remains negative overall, and a true recovery requires a turn in biotech and academic funding that has not arrived yet.
Recurring lab needs, cyclical budgets
Bio-Rad sells more than 12,000 products and services. The list includes reagents, lab apparatus, equipment, quality controls, and blood typing products. Many customers need the same supplies again and again, which adds a recurring piece to revenue.
Customers include universities, biotech companies, hospitals, labs, schools, governments, and health systems. That mix helps spread risk, but it also ties demand to budgets. When universities or biotech firms cut spending, Life Science can fall fast.
Clinical Diagnostics is the larger segment. In Q2 2026 it made up about 61.3% of sales, while Life Science made up about 38.7%. The diagnostics business is usually steady, but it can be hurt by foreign reimbursement changes or regional conflicts.
Bio-Rad is highly global. In Q2 2026, about 39% of sales came from the United States and 61% from international markets. That reach brings growth chances, but also currency swings, trade rules, local regulations, and conflict risk.
What Bio-Rad sells
Life Science research tools
These tools help researchers separate, identify, analyze, and purify biological materials. This area can grow when academic, biotech, and biopharma funding improves, but current demand is weak.
Clinical quality controls
Quality controls help labs check that tests are working correctly. These are a steady driver of Diagnostics demand.
Blood typing products
Blood typing products support clinical testing. They are part of the Diagnostics base and helped the segment avoid a decline in Q2 2026.
Reagents and consumables
Reagents are chemical or biological supplies used in tests and experiments. These can repeat as customers keep running the same workflows.
Lab apparatus and equipment
Bio-Rad sells instruments and equipment used in research and testing. These purchases can be delayed when funding is tight.
Acquired research programs
Recent acquired programs have not all worked as planned. In 2025, Bio-Rad recorded more than $200 million of in-process research and development impairments tied to Dropworks and Curiosity.
Two segments, mixed directions
Sales mix is from Q2 2026: about 38.7% Life Science and 61.3% Clinical Diagnostics. Diagnostics grew slightly while Life Science declined.
What could break the thesis
Life Science funding stays weak
High impact · High oddsLife Science sales fell 5.1% currency-neutral in Q2 2026. Management tied the decline to ongoing academic research weakness. If universities, biotech firms, and government labs keep cutting or delaying purchases, the segment will continue to shrink.
Diagnostics faces Middle East pressure
High impact · Medium oddsClinical Diagnostics grew 0.3% currency-neutral in Q2 2026, but management noted that regional conflicts in the Middle East have hurt demand and logistics in EMEA. If that pressure lasts or spreads, the segment could turn negative again.
Margin recovery remains fragile
High impact · Medium oddsConsolidated gross margin was 53.1% in Q2 2026, up slightly from 53.0% a year earlier. While this shows stabilization, margins were hurt heavily in 2025 by higher material costs and inventory write-offs. The company must prove it can expand margins back to historical levels.
M&A capital gets questioned
Medium impact · Medium oddsBio-Rad recorded more than $200 million of in-process research and development impairments in 2025 tied to Dropworks and Curiosity. That raises a fair question about deal selection and integration. Future acquisitions may face more investor doubt.
Sartorius stake distorts results
Medium impact · High oddsBio-Rad has a large equity position in Sartorius AG. Changes in that market value can materially affect reported financial results, even when the core lab and diagnostics business has not changed much. Investors need to separate operating trends from investment gains or losses.
Global rules and currency bite
Medium impact · Medium oddsAbout 61% of Q2 2026 sales came from outside the United States. That exposes Bio-Rad to currency moves, trade limits, local tenders, and medical product rules such as FDA and foreign diagnostics regulation. Delays or added compliance costs can slow launches and pressure prices.
In one breath
What does Bio-Rad Laboratories do?
Bio-Rad makes and sells products for life science research and clinical diagnostics. Its products include reagents, equipment, quality controls, and blood typing tools used by labs, hospitals, researchers, schools, and governments.
Why is Bio-Rad under pressure in 2026?
The Life Science segment is hurt by weak academic research funding. At the same time, the Clinical Diagnostics segment is fighting demand and logistics pressure from Middle East conflicts affecting the EMEA region.
What would make the Bio-Rad story improve?
The clearest signs would be Life Science sales growing again, Diagnostics demand improving in EMEA, and gross margin expanding well past the 53.1% level reported in Q2 2026.
Why does Sartorius AG matter to Bio-Rad investors?
Bio-Rad owns a large equity stake in Sartorius AG. Moves in that stake can swing reported net income, so investors should compare those swings with the performance of Bio-Rad's core operating business.
